I think it's pretty simple. Awful, desperate, financings were done because the co. had no better alternatives and they crushed the stock price. The market cap is a different calculation, number of shares out and also the fully diluted number, with an authorization up to 500M coming soon. Slow sales progress led to those financings despite major cost cutting. So now the only way out of the mess is very large profitable sales and soon. Turkey? Check. Kenya? Soon. 2016? Looks promising if one can see beyond the haze of pain.
What is your id there, holycow? Quality over Quantity! I post my honest thoughts there and wish others would do the same, if any are new to gthp feel free to query but better to study independently.
I hate yahoo, I use investor village so would prefer if you and others would go to gthp board there. I'm done here for now, yazoo is awful. It's free to join IV
Because it's too early for that, company needs to prove itself first. Would need a sales annual run rate of $10-20M and/or FDA approval before that will happen. This is what Guided told us. I've studied this one thoroughly since Feb. 2013 and have studied the competition as well. CEO has many great contacts and he keeps them informed of progress.
Don't get hung up on PRs not saying sold. Do you know this company and its customers at all? Might want to read all the recent filings, 10q and all the 8ks with exhibits. I think it will survive and eventually thrive but it's going to take time. If things go to plan they can achieve positive operating cash flow in 2016. Most customers buy one or two devices to evaluate before placing orders, while some are evaluating all the performance data and skipping their own evaluations. Customer testing was done compared to the gold standard of biopsies and none have failed that, 4 or 5 are still evaluating. There is great interest in China and negotiations are underway. Teleconference transcripts should be read.
Lilith you are so wrong it's hard to believe you type that junk. One device can generate up to 10,000 disposable cervical guides per year at high gross margins.
They await FDA approval. In the meantime, guided is building a market overseas, and only needs $10/year to b/e. If they achieve that, won't need a partner, won't need to sell the co. The distributors are their partners. All this bearishness is great, it means there is only upside if and when they execute.
Lilith, we all know what is obvious, ugly financings, not enough revenues. The stock price reflects all what is going on. The company and its long stock holders see a way to success. I know it will be difficult and take some time but if they succeed and I believe they will, the upside is very large, multiples of today's stock price. I see no point in reiterating all that is so well-known. I prefer to focus on what is happening today and likely to happen over the next 3, 6, 18 months. Kenya, Turkey, and many other nations want Luviva soon.
I believe guided can execute a profitable licensing arrangement in Asia.
With sales booked, financings will be better, that's just common sense. With 99% efficacy no one should say Luviva doesn't work.
Lilith, I am so disappointed! I want at least 10 thumbs down on that TA post. They won't, can't, shouldn't, r/s until/unless the stock is much higher. Stocks go up and down, my plan is to make money on them regardless, trading and speculating.
We'll know soon! 5 indicators say so, and a wild looking candle, today's buyers appear cheerful.
You're correct about what, every 5 yrs? I already forgot what you posted this morn. I want to see foreign women get luviva'd en masse and soon! In the tens of millions.
Ok so in this case the guidelines I posted of May 1 are accurate. Most every 3, some every 5.
What I'm focused on and why I'm long here is int. sales, and co. only needs $10m/year to break even. In Turkey, Kenya, almost none have been screened so almost all in that age group need to be screened asap and that is a lot of cervical guides at gross margins over 60%. I think they can get money on good terms to mfg. the luvivas and order the CG. The link I posted came from the business news. I know some women who insist on full screenings every year in u.s.
for foreign sales and licensings. FDA approval is way off in the future now.
They make good gm on the cervical guides in the Turkey order. Only need $10m annual sales revenues to b/e and that one order took them over a third of the way to b/e, so said ceo.